A Phase 3 interventional study of abatacept and Methotrexate (MTX) in Rheumatoid Arthritis (RA), sponsored by Bristol-Myers Squibb. Completed at 22 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-23.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 31st largest by enrollment, is one of 6 that started in 2007, is one of 26 in phase 3, and was the 18th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 6 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 31st largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2007, is one of 22 in phase 3, and was the 20th registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
To evaluate safety and immunogenicity of abatacept when used with or without methotrexate in the absence of an IV loading dose of abatacept
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants were also administered a stable MTX dose of greater than or equal to 10 mg once weekly for at least 4 weeks prior to first injection of SC abatacept.
Drug: abatacept · Drug: Methotrexate (MTX)
In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants did not receive MTX at screening i.e., MTX naive, or discontinued MTX due to lack of efficacy or tolerability at least 4 weeks prior to first injection of SC abatacept.
Drug: abatacept
solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open
Also known as: BMS-188667, Orencia®
Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (Enzyme-linked Immunosorbent Assay [ELISA] Method) at Day 113 of the ST Study
ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.
Time frame: Day 113
Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (ELISA Method) Over Time During the ST Study
ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.
Time frame: Day 15, 29, 43, 57, 85,113 and 28, 56, and 85 days post last dose.
Number of Participants With Positive Anti-abatacept Responses to Abatacept (Meso-Scale Discovery [MSD] Electrochemiluminescence [ECL] Assay Method) Over Time During the ST Study
The ECL (MSD) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. It is more sensitive and has a higher drug tolerance than ELISA method. For the anti-abatacept antibody ECL (MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10.
Time frame: Day 15, 29, 43, 57, 85,113 and 28, 56 and 85 days post last dose.
Immunogenicity in MTX Naive and MTX-previous Users in Cohort 1 at Day 113 of the ST Study (for ELISA Results)
ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.
Time frame: Day 113.
Immunogenicity in MTX Naive and MTX-previous Users in Cohort 1 at Day 113 of the ST Study (for MSD Results)
The ECL (MSD) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. It is more sensitive and has a higher drug tolerance than the ELISA method. For anti-abatacept antibody ECL (MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10.
Time frame: Day 113.
Cross Tabulations of the Number of Participants With Positive and Negative Immunogenicity Status at Baseline and Each Visit During the ST Study (for ELISA Results)
ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.
Time frame: Baseline and on day 15, 29, 43, 57, 85 and 113
Cross Tabulations of the Number of Participants With Positive and Negative Immunogenicity Status at Baseline and Each Visit During the ST Study (for MSD Results)
The ECL (MSD) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum . It is more sensitive and has a higher drug tolerance than the ELISA method. For anti-abatacept antibody ECL(MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10.
Time frame: Baseline and day 15, 29, 43, 57, 85 and 113.
Change From Baseline in DAS28-CRP Score at End of 4-month (Day 113) of the ST Study
DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joint out of 28, the number of swollen joint out of 28, C-reactive protein (CRP) in milligrams/Liter (mg/L) and subject assessment of disease activity measure on a VAS of 100mm. DAS 28 = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(CRP+1) + 0.014 \* VAS + 0.96.
Time frame: Baseline and Month 4 (Day113).
Number of Participants With Clinically Meaningful Improvement at End of 4-month (Day 113) of the ST Study
A clinically meaningful improvement is defined as a greater than or equal to 1.2 reduction in DAS28-CRP score from baseline.
Time frame: Day 113.
Change From Baseline in Physical Functioning (HAQ-DI) at End of the 4-month Treatment Period (Day 113) of the ST Study
HAQ-DI takes into account participant's use of aids or devices or assistance in scoring algorithm for a disability category. The questionnaire includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score is calculated by summing worst scores in each domain and dividing by the number of domains answered.
Time frame: Baseline and Month 4 (Day 113).
Change From Baseline in All HAQ-DI Components at End of the 4-month Treatment Period (Day 113) of the ST Study
HAQ-DI takes into account participant's use of aids or devices or assistance in scoring algorithm for a disability category. The questionnaire includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score is calculated by summing worst scores in each domain and dividing by the number of domains answered.
Time frame: Baseline and Month 4 (Day113).
Cross Tabulations of Number of Participants With Positive and Negative Status for RF at Day 113 With Baseline, in the ST Study
RF is an autoantibody that is usually present in the serum of people with rheumatoid arthritis. The cut-point value for seroconversion was 15 IU/mL (\>= 15 IU/mL resulted in a positive result). Cross-tabulation of frequency of seroconversion of RF at Day 113 with baseline, in the ST period, was provided.
Time frame: Baseline and Day 113.
Number of Participants Who Died, Experienced SAEs, Experienced AEs or Who Discontinued Due to AEs During the ST Study
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs or SAEs were recorded.
Time frame: Continuously through ST period (upto Day 113). Includes the data from start of study drug therapy up to 56 days after the last dose (Day 113) or start of the long-term period whichever occurred first.
Number of Participants Who Experienced Drug-related SAEs and Drug-related AEs During the ST Study
Drug-related AEs are those events with a relationship to the study therapy of certain; probable; possible; or missing. Drug-related SAEs are those events with any relationship to the study therapy.
Time frame: Continuously through ST period (upto Day 113). Includes the data from start of study drug therapy up to 56 days after the last dose (Day 113) or start of the long-term period whichever occurred first.
Number of Participants With AEs of Special Interest During the ST Study
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, AEs of particular importance were associated with the use of immunomodulatory agents: infections, autoimmune disorders, malignancies, and injection reaction AEs (systemic AEs occurring within 24 hours of SC injection and local injection site reactions) were recorded.
Time frame: Continuously through ST period (up to Day 113). Includes the data from start of study drug therapy up to 56 days after the last dose (Day 113) or start of the long-term period whichever occurred first.
Number of Participants With Marked Abnormalities (MAs) in Hematology During the ST Study: Hemoglobin, Hematocrit, Platelet Count, Erythrocytes and Leukocytes
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre Rx); hematocrit: \<0.75 \* pre-Rx value; platelet count: \<0.67 \* (LLN -lower limit of normal) (or, if pre-Rx value \<LLN, then \<0.5 \* pre-Rx value and \<100,000/mm\^3); leukocytes: \<0.75 \* LLN or \>1.25 \* ULN (or, if pre-Rx value \<LLN, then \<0.8 \* pre-Rx or \>(ULN -upper limit of normal) ; erythrocytes: \<0.75 \* pre Rx.
Time frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Number of Participants With MAs in Hematology During the ST Study: Neutrophils + Bands (Absolute), Lymphocytes (Absolute), Monocytes (Absolute), Basophils (Absolute) and Eosinophils (Absolute)
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Neutrophils + bands (absolute): \<1.00 \* 10\^3cells/microlitre (uL); lymphocytes (absolute): \<0.75 \* 10\^3 cells/uL or \>7.50 \* 10\^3 cells/uL; monocytes (absolute): \>2.00 \* 10\^3 cells/uL; basophils (absolute): \>0.40 \* 10\^3 cells/uL; eosinophils (absolute): \>0.75 \* 10\^3 cells/uL.
Time frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Number of Participants With MAs in Serum Chemistry During the ST Study: Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Bilirubin (Total), G-Glutamyl Transferase (G-GT) and Blood Urea Nitrogen (BUN)
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP: \>2.0 \* ULN (if pre-Rx \> ULN, then \>3 \* pre-Rx); AST, ALT: \> 3 \* ULN (if pre-Rx \> ULN, then \> 4 \* pre-Rx); bilirubin (total): \>2 \* ULN, or if pre Rx \> ULN then \>4 \* Pre Rx; BUN : \>2 \* pre Rx; GGT : \>2 \* ULN, or if pre Rx \> ULN then \>3 \* pre Rx.
Time frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Number of Participants With MAs in Serum Chemistry During the ST Study: Creatinine, Sodium (Serum), Potassium (Serum), Chloride (Serum), Calcium (Total) and Protein (Total)
MAs= laboratory measurements marked as abnormal: creatinine: \>1.5 \* pre-Rx; sodium (serum):\<0.95 \* LLN or \>1.05 \* ULN (if pre-Rx \< LLN, then \<0.95 \* pre-Rx or \>1.05 \* ULN. If pre-Rx \> ULN, then \>0.95 \* pre-Rx or \< ULN); potassium (serum):\<0.9 \* LLN or \>1.1 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN; chloride (serum),protein (total):\<0.9 \* LLN or \>1.1 8 ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>1.1 \* pre-Rx or \< LLN); calcium (total): \<0.8 \* LLN or \>1.2 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>0.75 \* pre-Rx or \< ULN).
Time frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Number of Participants With MAs in Serum Chemistry During the ST Study: Glucose (Fasting Serum), Albumin, Glucose (Serum), Phosphorous (Inorganic) and Uric Acid
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. Glucose (fasting serum): \<0.8 \* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<2.0 \* pre-Rx or \>ULN; albumin: \<0.9 \* LLN (if pre-Rx \< LLN, then \<0.75 \* pre-Rx); uric acid: \>1.5 \* ULN (if pre-Rx \> ULN, then \>2.0 \* pre-Rx); phosphorous (inorganic):\<0.75 \* LLN or \>1.25 \* ULN (if pre-Rx \< ULN, then \<0.67 \* pre-Rx or \< ULN. If pre-Rx \> ULN, then \>1.33 \* re-Rx or \< LLN); glucose (serum): \<65 mg/dL or \>220 mg/dL.
Time frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Number of Participants With MAs in Urinalysis During the ST Study: Protein, Glucose, Blood, Leukocyte Esterase, Red Blood Cells (RBC) and White Blood Cells (WBC)
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis: protein, glucose, blood, leukocyte esterase, RBC, WBC: \>= 2+ (or, if value \>= 4, or if pre-Rx value = 0 or 0.5, then \>= 2x or if pre-Rx value =1, then \>= 3, or if pre-Rx = 2 or 3, then \>= 4).
Time frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.
Number of Participants With Anti-nuclear Antibody (ANA) Category at Day 113 of the ST Study
ANA status was categorized as negative or positive corresponding to the following dilutions: less than 1:160 and greater than equal to 1:160.
Time frame: Day 113.
Number of Participants With Anti-double Stranded DNA (dsDNA) Category at Day 113 of the ST Study
Anti-dsDNA antibody status was categorized as negative or positive based upon assay-specific numeric cut-off values.
Time frame: Day 113.
Number of Participants With Clinically Meaningful Vital Signs During the ST Study
Vital signs measurements (including seated blood pressure, heart rate and temperature) were recorded. The investigator used his/her clinical judgment to decide whether or not abnormalities in vital signs/physical examination were clinically meaningful.
Time frame: At screening and on days 1,15,29,43, 57, 85 and 113.
Minimum Plasma Concentration (Cmin) at Each Visit During the 4 Month Treatment Period of the ST Study
Cmin serum abatacept concentration was obtained directly from the concentration-time data.
Time frame: Days 1, 15, 29, 43, 57, 85 and 113.
Number of Participants With Abatacept Induced Antibody Responses Over Time During the LTE Study (ECL Method) - All Treated Participants in LTE Study
The Meso-Scale Discovery (MSD) electrochemiluminescence (ECL) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. It is more sensitive and has a higher drug tolerance than ELISA method. For the anti-abatacept antibody ECL (MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10. Antibody responses included CTLA4 and possibly immune globulin (IG), IG and/or junction region.
Time frame: Days 197, 281, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541, 1625, 1709, 1821, 1989, days post dose: 28, 56, 85, 168
Change From Baseline in DAS28-CRP Score in the LTE Study - All Treated Participants in LTE Study
DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of 28, the number of swollen joints out of 28, C-reactive protein (CRP) in milligrams/Liter (mg/L) and subject assessment of disease activity measure on a VAS of 100mm. DAS 28 = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(CRP+1) + 0.014 \* VAS + 0.96. Baseline was Day 1 of the ST Study; Day 113 was the end of the ST Study.
Time frame: Baseline, Day 113, Day 1345
Number of Participants With Clinically Meaningful Improvement From Baseline in the LTE Study - All Treated Participants in LTE Study
A clinically meaningful improvement is defined as a greater than or equal to 1.2 reduction in DAS28-CRP score from baseline. Baseline was Day 1 of the ST Study. Day 113 was the end of the ST Study.
Time frame: Baseline, Day 113, Day 1345
Number of Participants in DAS28-CRP Remission and Number of Participants With Low Disease Activity (LDA) in the LTE Study - All Treated Participants in the LTE
DAS28-CRP remission was defined as DAS28-CRP less than 2.6 and LDA was defined as DAS28-CRP less than, equal to 3.2. End of ST Study was Day 113.
Time frame: Day 113, Day 1345
Change From Baseline in HAQ-DI in the LTE Study - All Treated Participants in LTE Study
HAQ-DI takes into account participant's use of aids or devices or assistance in scoring algorithm for a disability category. The questionnaire includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score is calculated by summing worst scores in each domain and dividing by the number of domains answered. Baseline was Day 1 in the ST Study and Day 113 was the last day of the ST Study.
Time frame: Baseline, Day 113, Day 1345
Number of Participants With HAQ Responses in the LTE Study - All Treated Participants in the LTE STudy
HAQ response was defined as an improvement of at least 0.3 units from baseline in the HAQ Disability Index (HAQ DI). Baseline was Day 1 of the ST Study and Day 113 was the last day of the ST Study.
Time frame: Baseline, Day 113, Day 1345
Number of Participants With Negative Status for RF up to 7 Days After Last Dose of Abatacept in the LTE Period - All Treated Participants in LTE Study
RF is an autoantibody that is usually present in the serum of people with rheumatoid arthritis. The cut-point value for seroconversion was 15 IU/mL (\>= 15 IU/mL resulted in a positive result).
Time frame: Continuously from start of LTE period up to 7 days post the last dose
Change From Baseline in DAS28-CRP Score and Physical Function (HAQ-DI) Score in the LTE Study - Abatacept Monotherapy Subgroup
Abatacept Monotherapy Subgroup consisted of participants who received SC abatacept and did not receive MTX in the ST and LTE Studies. DAS28-CRP: continuous variable which is a composite of 4 variables:number of tender joints out of 28, number of swollen joints out of 28, C-reactive protein (CRP) in mg/L and self assessment of disease activity measure on a VAS of 100mm. DAS 28 = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(CRP+1) + 0.014 \* VAS + 0.96. HAQ-DI includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score sums worst scores in each domain and divides by the number of domains answered. Baseline was Day 1 of Short Term Study. Day 113 was the last day of the Short Term Study.
Time frame: Baseline, Day 113, Day 1345
Number of Participants in DAS 28-CRP Remission and Low Disease Activity (LDA) in the LTE Study - Abatacept Monotherapy Subgroup
Remission was defined as DAS 28-CRP \< 2.6 and LDA was defined as DAS 28-CRP \<= 3.2. End of ST Study was Day 113. Abatacept Monotherapy Subgroup was defined as those participants who received as at least 1 dose of abatacept and did not receive MTX in the ST and LTE Studies.
Time frame: Day 113, Day 1345
Number of Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs), or Discontinued Due to AEs and/or SAEs During the LTE Period - All Treated Participants in LTE Study
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Drug-related AEs/SAEs are those events with a relationship to the study therapy of certain; probable; possible; or missing.
Time frame: Continuously from start of LTE Study up to 56 days post the last dose
Number of Participants With AEs of Special Interest During the LTE Study - All Treated Participants in LTE Study
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, AEs of particular importance were associated with the use of immunomodulatory agents: infections, autoimmune disorders, malignancies, and injection reaction AEs (systemic AEs occurring within 24 hours of SC injection and local injection site reactions) were recorded.
Time frame: Continuously from start of LTE Study up to 56 days post the last dose
Number of Participants With Marked Abnormalities (MAs) in Hematology During the LTE Period - All Treated Participants in LTE Study
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre Rx); hematocrit: \<0.75 \* pre-Rx value; platelet count: \<0.67 \* (LLN -lower limit of normal) (or, if pre-Rx value \<LLN, then \<0.5 \* pre-Rx value and \<100,000/mm\^3); leukocytes: \<0.75 \* LLN or \>1.25 \* ULN (or, if pre-Rx value \<LLN, then \<0.8 \* pre-Rx or \>(ULN -upper limit of normal) ; erythrocytes: \<0.75 \* pre Rx. Neutrophils + bands (absolute): \<1.00 \* 10\^3cells/microlitre (uL); lymphocytes (absolute): \<0.75 \* 10\^3 cells/uL or \>7.50 \* 10\^3 cells/uL; monocytes (absolute): \>2.00 \* 10\^3 cells/uL; basophils (absolute): \>0.40 \* 10\^3 cells/uL; eosinophils (absolute): \>0.75 \* 10\^3 cells/uL.
Time frame: Continuously from start of LTE Study up to 56 days post the last dose
Number of Participants With MAs in Serum Chemistry (Liver and Kidney Function) During the LTE Period - All Treated Participants in LTE Study
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Bilirubin (Total), G-Glutamyl Transferase (G-GT), Blood Urea Nitrogen (BUN) and Creatinine MA criteria: ALP: \>2.0 \* ULN (if pre-Rx \> ULN, then \>3 \* pre-Rx); AST, ALT: \> 3 \* ULN (if pre-Rx \> ULN, then \> 4 \* pre-Rx); bilirubin (total): \>2 \* ULN, or if pre Rx \> ULN then \>4 \* Pre Rx; BUN : \>2 \* pre Rx; GGT : \>2 \* ULN, or if pre Rx \> ULN then \>3 \* pre Rx; creatinine: \>1.5 \* pre-Rx.
Time frame: Continuously from start of LTE Study up to 56 days post the last dose
Number of Participants With MAs in Serum Chemistry (Electrolytes, Glucose, Protein, and Metabolite) During the LTE Period - All Treated Participants in LTE Study
Sodium (serum):\<0.95 \* LLN or \>1.05 \* ULN (if pre-Rx \< LLN, then \<0.95 \* pre-Rx or \>1.05 \* ULN. If pre-Rx \> ULN, then \>0.95 \* pre-Rx or \< ULN); potassium (serum):\<0.9 \* LLN or \>1.1 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN; chloride (serum),protein (total):\<0.9 \* LLN or \>1.1 8 ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>1.1 \* pre-Rx or \< LLN); calcium (total): \<0.8 \* LLN or \>1.2 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>0.75 \* pre-Rx or \< ULN); phosphorous (inorganic):\<0.75 \* LLN or \>1.25 \* ULN (if pre-Rx \< ULN, then \<0.67 \* pre-Rx or \< ULN. If pre-Rx \> ULN, then \>1.33 \* re-Rx or \<LLN); glucose (serum): \<65 mg/dL or \>220 mg/dL; Glucose (fasting serum): \<0.8 \* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<2.0 \* pre-Rx or \>ULN; albumin: \<0.9 \* LLN (if pre-Rx \< LLN, then \<0.75 \* pre-Rx); uric acid: \>1.5 \* ULN (if pre-Rx \> ULN, then \>2.0 \* pre-Rx).
Time frame: Continuously from start of LTE Study up to 56 days post the last dose
Number of Participants With MAs in Urinalysis During the LTE Period: Protein, Glucose, Blood, Leukocyte Esterase, Red Blood Cells (RBC) and White Blood Cells (WBC) - All Treated Participants in LTE Study
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis: protein, glucose, blood, leukocyte esterase, RBC, WBC: \>= 2+ (or, if value \>= 4, or if pre-Rx value = 0 or 0.5, then \>= 2x or if pre-Rx value =1, then \>= 3, or if pre-Rx = 2 or 3, then \>= 4).
Time frame: Continuously from start of LTE Study up to 56 days post the last dose
Short term (ST) Study results (2 arms) were released in 2010. Final long term extension (LTE) results (1 arm with pooled data), up to 2014, are now included. During the LTE Study, 125 mg abatacept, was continued to be self-administered weekly and adjustments to RA medications including MTX were permitted at investigators discretion.
| Milestone | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Cohort |
|---|---|---|
| Started | 51 | 49 |
| Completed | 50 | 45 |
| Not completed | 1 | 4 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Withdrawal of consent | 0 | 1 |
| Withdrew: Primary endpoint evaluation not complete | 0 | 1 |
| Milestone | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Cohort |
|---|---|---|
| Started | 0 | 90 |
| Completed | 0 | 59 |
| Not completed | 0 | 31 |
| Withdrew: Lack of efficacy | 0 | 14 |
| Withdrew: Adverse event | 0 | 9 |
| Withdrew: Lost to follow-up | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Other | 0 | 2 |
| Withdrew: Poor/non-compliance | 0 | 1 |
ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (Enzyme-linked Immunosorbent Assay [ELISA] Method) at Day 113 of the ST Study | 0 | 0 |
DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joint out of 28, the number of swollen joint out of 28, C-reactive protein (CRP) in milligrams/Liter (mg/L) and subject assessment of disease activity measure on a VAS of 100mm. DAS 28 = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(CRP+1) + 0.014 \* VAS + 0.96.
| Units on a scale | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Change From Baseline in DAS28-CRP Score at End of 4-month (Day 113) of the ST Study | -1.67 (-2.06 to -1.28) | -1.94 (-2.46 to -1.42) |
ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Day 15, (n= 51,47) | 0 | 0 |
| Day 29, (n= 50,48) | 2 | 0 |
| Day 43, (n= 50,48) | 2 | 0 |
| Day 57, (n= 50,47) | 1 | 1 |
| Day 85, (n= 50,47) | 0 | 0 |
| Day 113, (n= 50,45) | 0 | 0 |
| Overall on Treatment visits, (n=51,49) | 2 | 1 |
| 28 Days last post dose, (n=2,3) | 0 | 0 |
| 56 Days last post dose, (n=2,3) | 0 | 0 |
| 85 Days last post dose, (n=4,4) | 0 | 1 |
| Overall post visits, (n=4,4) | 0 | 1 |
| Overall, (n=51,49) | 2 | 2 |
The ECL (MSD) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. It is more sensitive and has a higher drug tolerance than ELISA method. For the anti-abatacept antibody ECL (MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10.
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Day 15, (n= 51,47) | 1 | 1 |
| Day 29, (n= 50,48) | 1 | 0 |
| Day 43, (n= 50,48) | 1 | 0 |
| Day 57, (n= 50,47) | 1 | 0 |
| Day 85, (n= 50,47) | 1 | 0 |
| Day 113, (n=50,45) | 1 | 0 |
| Overall on Treatment visits, (n=51,49) | 1 | 1 |
| 28 Days last post dose, (n=2,3) | 0 | 0 |
| 56 Days last post dose, (n=2,3) | 0 | 0 |
| 85 Days last post dose, (n=4,4) | 0 | 1 |
| Overall post visits, (n=4,4) | 0 | 1 |
| Overall, (n=51,49) | 1 | 2 |
ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.
No measurements were reported for this outcome.
The ECL (MSD) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. It is more sensitive and has a higher drug tolerance than the ELISA method. For anti-abatacept antibody ECL (MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10.
No measurements were reported for this outcome.
ELISA is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 25.
No measurements were reported for this outcome.
The ECL (MSD) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum . It is more sensitive and has a higher drug tolerance than the ELISA method. For anti-abatacept antibody ECL(MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10.
No measurements were reported for this outcome.
A clinically meaningful improvement is defined as a greater than or equal to 1.2 reduction in DAS28-CRP score from baseline.
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Number of Participants With Clinically Meaningful Improvement at End of 4-month (Day 113) of the ST Study | 30 | 30 |
HAQ-DI takes into account participant's use of aids or devices or assistance in scoring algorithm for a disability category. The questionnaire includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score is calculated by summing worst scores in each domain and dividing by the number of domains answered.
| Units on a scale | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Change From Baseline in Physical Functioning (HAQ-DI) at End of the 4-month Treatment Period (Day 113) of the ST Study | -0.31 (-0.43 to -0.19) | -0.58 (-0.74 to -0.42) |
HAQ-DI takes into account participant's use of aids or devices or assistance in scoring algorithm for a disability category. The questionnaire includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score is calculated by summing worst scores in each domain and dividing by the number of domains answered.
| Units on a scale | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Dressing and Grooming, (n= 50,46) | -0.44 (-0.63 to -0.25) | -0.57 (-0.79 to -0.34) |
| Arising, (n= 50,46) | -0.26 (-0.44 to -0.08) | -0.59 (-0.81 to -0.36) |
| Eating, (n= 50,46) | -0.28 (-0.50 to -0.06) | -0.57 (-0.85 to -0.28) |
| Walking, (n= 50,46) | -0.26 (-0.46 to -0.06) | -0.54 (-0.75 to -0.34) |
| Hygiene, (n= 49,46) | -0.33 (-0.55 to -0.10) | -0.43 (-0.65 to -0.22) |
| Reaching, (n= 49,46) | -0.24 (-0.47 to -0.02) | -0.50 (-0.74 to -0.26) |
| Gripping, (n= 49,46) | -0.31 (-0.54 to -0.07) | -0.76 (-1.04 to -0.48) |
| Activities, (n= 49,46) | -0.39 (-0.58 to -0.19) | -0.67 (-0.90 to -0.45) |
RF is an autoantibody that is usually present in the serum of people with rheumatoid arthritis. The cut-point value for seroconversion was 15 IU/mL (\>= 15 IU/mL resulted in a positive result). Cross-tabulation of frequency of seroconversion of RF at Day 113 with baseline, in the ST period, was provided.
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Negative at Baseline, negative at Day 113 | 12 | 15 |
| Negative at Baseline, positive at Day 113 | 2 | 0 |
| Positive at Baseline, negative at Day 113 | 1 | 1 |
| Positive at Baseline, positive at Day 113 | 32 | 29 |
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs or SAEs were recorded.
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Deaths | 0 | 0 |
| SAEs | 2 | 3 |
| AEs | 37 | 32 |
| All SAEs Leading to Discontinuation | 1 | 1 |
| All AEs Leading to Discontinuation | 3 | 1 |
Drug-related AEs are those events with a relationship to the study therapy of certain; probable; possible; or missing. Drug-related SAEs are those events with any relationship to the study therapy.
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Drug-related AEs | 14 | 12 |
| Drug-related SAEs | 1 | 1 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, AEs of particular importance were associated with the use of immunomodulatory agents: infections, autoimmune disorders, malignancies, and injection reaction AEs (systemic AEs occurring within 24 hours of SC injection and local injection site reactions) were recorded.
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Infections | 18 | 14 |
| Malignant neoplasm | 0 | 0 |
| Autoimmune disorders | 0 | 0 |
| Local injection reactions | 3 | 4 |
| Systemic injection reactions | 4 | 4 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre Rx); hematocrit: \<0.75 \* pre-Rx value; platelet count: \<0.67 \* (LLN -lower limit of normal) (or, if pre-Rx value \<LLN, then \<0.5 \* pre-Rx value and \<100,000/mm\^3); leukocytes: \<0.75 \* LLN or \>1.25 \* ULN (or, if pre-Rx value \<LLN, then \<0.8 \* pre-Rx or \>(ULN -upper limit of normal) ; erythrocytes: \<0.75 \* pre Rx.
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Low Hemoglobin | 0 | 0 |
| Low Hematocrit | 0 | 0 |
| Low Platelet Count | 0 | 0 |
| High Platelet Count | 0 | 0 |
| High Leukocytes | 1 | 2 |
| Low Erythrocytes | 0 | 0 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Neutrophils + bands (absolute): \<1.00 \* 10\^3cells/microlitre (uL); lymphocytes (absolute): \<0.75 \* 10\^3 cells/uL or \>7.50 \* 10\^3 cells/uL; monocytes (absolute): \>2.00 \* 10\^3 cells/uL; basophils (absolute): \>0.40 \* 10\^3 cells/uL; eosinophils (absolute): \>0.75 \* 10\^3 cells/uL.
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Low Neutrophils + Bands (absolute) | 0 | 0 |
| Low Lymphocytes (absolute) | 3 | 3 |
| High Lymphocytes (absolute) | 0 | 0 |
| High Monocytes (absolute) | 0 | 0 |
| High Basophils (absolute) | 0 | 0 |
| High Eosinophils (absolute) | 2 | 2 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP: \>2.0 \* ULN (if pre-Rx \> ULN, then \>3 \* pre-Rx); AST, ALT: \> 3 \* ULN (if pre-Rx \> ULN, then \> 4 \* pre-Rx); bilirubin (total): \>2 \* ULN, or if pre Rx \> ULN then \>4 \* Pre Rx; BUN : \>2 \* pre Rx; GGT : \>2 \* ULN, or if pre Rx \> ULN then \>3 \* pre Rx.
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| High ALP | 0 | 0 |
| High AST | 1 | 0 |
| High ALT | 1 | 0 |
| High GGT | 0 | 2 |
| High Bilirubin (total) | 0 | 0 |
| High BUN | 1 | 1 |
MAs= laboratory measurements marked as abnormal: creatinine: \>1.5 \* pre-Rx; sodium (serum):\<0.95 \* LLN or \>1.05 \* ULN (if pre-Rx \< LLN, then \<0.95 \* pre-Rx or \>1.05 \* ULN. If pre-Rx \> ULN, then \>0.95 \* pre-Rx or \< ULN); potassium (serum):\<0.9 \* LLN or \>1.1 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN; chloride (serum),protein (total):\<0.9 \* LLN or \>1.1 8 ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>1.1 \* pre-Rx or \< LLN); calcium (total): \<0.8 \* LLN or \>1.2 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>0.75 \* pre-Rx or \< ULN).
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| High Chloride (serum) | 0 | 0 |
| Low Chloride (serum) | 0 | 0 |
| High Calcium (total) | 0 | 0 |
| Low Calcium (total) | 0 | 0 |
| High Protein (total) | 0 | 0 |
| Low Protein (total) | 0 | 0 |
| High Creatinine | 0 | 1 |
| High Sodium (serum) | 0 | 0 |
| Low Sodium (serum) | 0 | 0 |
| Low Potassium (serum) | 1 | 0 |
| High Potassium (serum) | 0 | 0 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. Glucose (fasting serum): \<0.8 \* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<2.0 \* pre-Rx or \>ULN; albumin: \<0.9 \* LLN (if pre-Rx \< LLN, then \<0.75 \* pre-Rx); uric acid: \>1.5 \* ULN (if pre-Rx \> ULN, then \>2.0 \* pre-Rx); phosphorous (inorganic):\<0.75 \* LLN or \>1.25 \* ULN (if pre-Rx \< ULN, then \<0.67 \* pre-Rx or \< ULN. If pre-Rx \> ULN, then \>1.33 \* re-Rx or \< LLN); glucose (serum): \<65 mg/dL or \>220 mg/dL.
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| High Glucose (Fasting Serum) (n=8; n=21) | 0 | 0 |
| Low Glucose (Fasting Serum) (n=8; n=21) | 0 | 0 |
| Low Albumin (n=51; n=49) | 0 | 1 |
| Low Glucose (Serum) (n=51; n=49) | 6 | 1 |
| High Glucose(Serum) (n=51; n=49) | 2 | 1 |
| High Uric Acid (n=51; n=49) | 0 | 0 |
| High Phosphorous (inorganic) (n=51; n=49) | 0 | 0 |
| Low Phosphorous (inorganic) (n=51; n=49) | 1 | 1 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis: protein, glucose, blood, leukocyte esterase, RBC, WBC: \>= 2+ (or, if value \>= 4, or if pre-Rx value = 0 or 0.5, then \>= 2x or if pre-Rx value =1, then \>= 3, or if pre-Rx = 2 or 3, then \>= 4).
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| High Protein, urine (n= 51,49) | 0 | 2 |
| High Glucose, urine (n= 51,49) | 1 | 0 |
| High Blood, urine (n= 51,49) | 1 | 3 |
| High Leukocyte Esterase, urine (n= 18,17) | 2 | 3 |
| High WBC, urine (n= 15,19) | 3 | 6 |
| High RBC, urine (n= 12,17) | 1 | 7 |
ANA status was categorized as negative or positive corresponding to the following dilutions: less than 1:160 and greater than equal to 1:160.
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Negative | 36 | 32 |
| Positive | 11 | 12 |
Anti-dsDNA antibody status was categorized as negative or positive based upon assay-specific numeric cut-off values.
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Negative | 41 | 37 |
| Positive | 4 | 8 |
Vital signs measurements (including seated blood pressure, heart rate and temperature) were recorded. The investigator used his/her clinical judgment to decide whether or not abnormalities in vital signs/physical examination were clinically meaningful.
| participants | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Number of Participants With Clinically Meaningful Vital Signs During the ST Study | 0 | 0 |
Cmin serum abatacept concentration was obtained directly from the concentration-time data.
| microgram/mL | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort |
|---|---|---|
| Day 15, (n= 40,41) | 13.69 (4.80 to 27.40) | 11.23 (2.70 to 27.10) |
| Day 29, (n= 49,45) | 19.39 (6.10 to 41.80) | 15.64 (4.40 to 42.20) |
| Day 43, (n= 41,38) | 23.40 (10.80 to 44.40) | 18.06 (5.20 to 48.10) |
| Day 57, (n= 48,38) | 24.38 (10.90 to 41.10) | 21.71 (9.60 to 68.00) |
| Day 85, (n= 47,39) | 28.77 (11.30 to 69.20) | 20.38 (2.60 to 50.00) |
| Day 113, (n=46,37) | 28.46 (10.10 to 66.50) | 23.74 (6.60 to 70.80) |
The Meso-Scale Discovery (MSD) electrochemiluminescence (ECL) assay method is a validated, sensitive assay technique used to analyze presence of abatacept-specific antibodies in serum. It is more sensitive and has a higher drug tolerance than ELISA method. For the anti-abatacept antibody ECL (MSD) assay, a sample was considered seropositive if it had a titer of 10 or greater and if immunodepletion was observed with abatacept, or abatacept and CTLA4-T. Those responses that were not positive in the initial screen or were not confirmed to be positive based on immunodepletion were reported as seronegative and were assigned a value of \< 10. Antibody responses included CTLA4 and possibly immune globulin (IG), IG and/or junction region.
| participants | Abatacept Long Term Extension (LTE) Study |
|---|---|
| Days 197, 281, 365, 449 (n=86, 87, 85, 79) | 0 |
| Day 533 (n=76) | 1 |
| Days 617, 729, 813 (n=74, 70, 66) | 0 |
| Days 897, 981 (n=66, 58) | 0 |
| Day 1093 (n=65) | 2 |
| Day 1177 (n=8) | 0 |
| Day 1261 (n=57) | 1 |
| Day 1345 (n=24) | 0 |
| Day 1457 (n=59) | 3 |
| Day 1541 (n=24) | 1 |
| Day 1625 (n=18) | 2 |
| Days 1709, 1821 (n=2, 11) | 0 |
| Day 1989 (n=13) | 1 |
| Overall on Treatment (n=88) | 11 |
| 28 days post last dose (n=18) | 0 |
| 56 days post last dose (n=15) | 2 |
| 85 days post last dose (n=16) | 2 |
| 168 days post last dose (n=3) | 2 |
| Overall post last dose visits (n=23) | 4 |
| Overall (n=90) | 13 |
DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of 28, the number of swollen joints out of 28, C-reactive protein (CRP) in milligrams/Liter (mg/L) and subject assessment of disease activity measure on a VAS of 100mm. DAS 28 = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(CRP+1) + 0.014 \* VAS + 0.96. Baseline was Day 1 of the ST Study; Day 113 was the end of the ST Study.
| Units on a scale | Abatacept Long Term Extension Study |
|---|---|
| Day 113 (n=88) | -1.89 (-2.2 to -1.5) |
| Day 1345 (n=61) | -2.39 (-2.8 to -1.9) |
A clinically meaningful improvement is defined as a greater than or equal to 1.2 reduction in DAS28-CRP score from baseline. Baseline was Day 1 of the ST Study. Day 113 was the end of the ST Study.
| participants | Abatacept Long Term Extension Study |
|---|---|
| Day 113 (n=88) | 59 |
| Day 1345 (n=61) | 43 |
DAS28-CRP remission was defined as DAS28-CRP less than 2.6 and LDA was defined as DAS28-CRP less than, equal to 3.2. End of ST Study was Day 113.
| participants | Abatacept Long Term Extension Study |
|---|---|
| Remission at Day 113 (n=90) | 28 |
| Remission at Day 1345 (n=63) | 28 |
| LDA at Day 113 (n=90) | 45 |
| LDA at Day 1345 (n=63) | 37 |
HAQ-DI takes into account participant's use of aids or devices or assistance in scoring algorithm for a disability category. The questionnaire includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score is calculated by summing worst scores in each domain and dividing by the number of domains answered. Baseline was Day 1 in the ST Study and Day 113 was the last day of the ST Study.
| units on a scale | Abatacept Long Term Extension Study |
|---|---|
| HAQ-DI at Day 113 (n=89) | -0.47 (-0.57 to -0.36) |
| HAQ-DI at Day 1345 (n=64) | -0.56 (-0.71 to -0.42) |
HAQ response was defined as an improvement of at least 0.3 units from baseline in the HAQ Disability Index (HAQ DI). Baseline was Day 1 of the ST Study and Day 113 was the last day of the ST Study.
| participants | Abatacept Long Term Extension Study |
|---|---|
| HAQ DI Response at Day 113 (n=89) | 53 |
| HAQ DI Response at Day 1345 (n=64) | 41 |
RF is an autoantibody that is usually present in the serum of people with rheumatoid arthritis. The cut-point value for seroconversion was 15 IU/mL (\>= 15 IU/mL resulted in a positive result).
| participants | Abatacept Long Term Extension Study |
|---|---|
| Number of Participants With Negative Status for RF up to 7 Days After Last Dose of Abatacept in the LTE Period - All Treated Participants in LTE Study | 20 |
Abatacept Monotherapy Subgroup consisted of participants who received SC abatacept and did not receive MTX in the ST and LTE Studies. DAS28-CRP: continuous variable which is a composite of 4 variables:number of tender joints out of 28, number of swollen joints out of 28, C-reactive protein (CRP) in mg/L and self assessment of disease activity measure on a VAS of 100mm. DAS 28 = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(CRP+1) + 0.014 \* VAS + 0.96. HAQ-DI includes 20 questions assessing physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 = unable to do. Higher scores indicate greater dysfunction. The score sums worst scores in each domain and divides by the number of domains answered. Baseline was Day 1 of Short Term Study. Day 113 was the last day of the Short Term Study.
| units on a scale | Abatacept Monotherapy Subgroup |
|---|---|
| DAS-CRP at Day 113 (n=31) | -2.42 ± 0.29 |
| DAS-CRP at Day 1345 (n=23) | -2.58 ± 0.30 |
| HAQ-DI at Day 113 (n=32) | -0.60 ± 0.10 |
| HAQ-DI at Day 1345 (n=25) | -0.65 ± 0.12 |
Remission was defined as DAS 28-CRP \< 2.6 and LDA was defined as DAS 28-CRP \<= 3.2. End of ST Study was Day 113. Abatacept Monotherapy Subgroup was defined as those participants who received as at least 1 dose of abatacept and did not receive MTX in the ST and LTE Studies.
| participants | Abatacept Monotherapy Subgroup |
|---|---|
| Remission at Day 113 (n=32) | 14 |
| Remission at Day 1345 (n=24) | 9 |
| LDA at Day 113 (n=32) | 18 |
| LDA at Day 1345 (n=24) | 13 |
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Drug-related AEs/SAEs are those events with a relationship to the study therapy of certain; probable; possible; or missing.
| participants | Abatacept Long Term Extension Study |
|---|---|
| Deaths | 0 |
| SAEs | 34 |
| Related SAEs | 6 |
| Discontinued due to SAEs | 3 |
| AEs | 86 |
| Related AEs | 34 |
| Discontinued due to AEs | 8 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, AEs of particular importance were associated with the use of immunomodulatory agents: infections, autoimmune disorders, malignancies, and injection reaction AEs (systemic AEs occurring within 24 hours of SC injection and local injection site reactions) were recorded.
| participants | Abatacept Long Term Extension Study |
|---|---|
| Infections | 69 |
| Autoimmune Disorders | 5 |
| Malignancies | 4 |
| Local Injection Site Reactions | 2 |
| Systemic Injection Reaction | 12 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre Rx); hematocrit: \<0.75 \* pre-Rx value; platelet count: \<0.67 \* (LLN -lower limit of normal) (or, if pre-Rx value \<LLN, then \<0.5 \* pre-Rx value and \<100,000/mm\^3); leukocytes: \<0.75 \* LLN or \>1.25 \* ULN (or, if pre-Rx value \<LLN, then \<0.8 \* pre-Rx or \>(ULN -upper limit of normal) ; erythrocytes: \<0.75 \* pre Rx. Neutrophils + bands (absolute): \<1.00 \* 10\^3cells/microlitre (uL); lymphocytes (absolute): \<0.75 \* 10\^3 cells/uL or \>7.50 \* 10\^3 cells/uL; monocytes (absolute): \>2.00 \* 10\^3 cells/uL; basophils (absolute): \>0.40 \* 10\^3 cells/uL; eosinophils (absolute): \>0.75 \* 10\^3 cells/uL.
| participants | Abatacept Long Term Extension Study |
|---|---|
| Low Hemoglobin (n=90) | 1 |
| Low Hematocrit (n=90) | 0 |
| Low Erythrocytes (n=90) | 0 |
| Low Platelet Count (n=89) | 0 |
| High Platelet Count (n=89) | 0 |
| Low Leukocytes (n=90) | 2 |
| High Leukocytes (n=90) | 5 |
| Low Neutrophils + bands | 0 |
| Low Lymphocytes (n=90) | 6 |
| High Lymphocytes (n=90) | 1 |
| High Monocytes (n=90) | 2 |
| High Basophils (n=90) | 0 |
| High Eosinophils (n=90) | 13 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Bilirubin (Total), G-Glutamyl Transferase (G-GT), Blood Urea Nitrogen (BUN) and Creatinine MA criteria: ALP: \>2.0 \* ULN (if pre-Rx \> ULN, then \>3 \* pre-Rx); AST, ALT: \> 3 \* ULN (if pre-Rx \> ULN, then \> 4 \* pre-Rx); bilirubin (total): \>2 \* ULN, or if pre Rx \> ULN then \>4 \* Pre Rx; BUN : \>2 \* pre Rx; GGT : \>2 \* ULN, or if pre Rx \> ULN then \>3 \* pre Rx; creatinine: \>1.5 \* pre-Rx.
| participants | Abatacept Long Term Extension Study |
|---|---|
| High ALP (n=90) | 0 |
| High AST (n=90) | 1 |
| High ALT (n=90) | 3 |
| High G-GT (n=90) | 2 |
| High Bilirubin (n=90) | 0 |
| High BUN (n=90) | 6 |
| High Creatinine (n=90) | 7 |
Sodium (serum):\<0.95 \* LLN or \>1.05 \* ULN (if pre-Rx \< LLN, then \<0.95 \* pre-Rx or \>1.05 \* ULN. If pre-Rx \> ULN, then \>0.95 \* pre-Rx or \< ULN); potassium (serum):\<0.9 \* LLN or \>1.1 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN; chloride (serum),protein (total):\<0.9 \* LLN or \>1.1 8 ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>1.1 \* pre-Rx or \< LLN); calcium (total): \<0.8 \* LLN or \>1.2 \* ULN (if pre-Rx \< LLN, then \<0.9 \* pre-Rx or \> ULN. If pre-Rx \> ULN, then \>0.75 \* pre-Rx or \< ULN); phosphorous (inorganic):\<0.75 \* LLN or \>1.25 \* ULN (if pre-Rx \< ULN, then \<0.67 \* pre-Rx or \< ULN. If pre-Rx \> ULN, then \>1.33 \* re-Rx or \<LLN); glucose (serum): \<65 mg/dL or \>220 mg/dL; Glucose (fasting serum): \<0.8 \* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<2.0 \* pre-Rx or \>ULN; albumin: \<0.9 \* LLN (if pre-Rx \< LLN, then \<0.75 \* pre-Rx); uric acid: \>1.5 \* ULN (if pre-Rx \> ULN, then \>2.0 \* pre-Rx).
| participants | Abatacept Long Term Extension Study |
|---|---|
| High and/or Low Sodium (n=90) | 0 |
| Low Potassium (n=90) | 2 |
| High Potassium (n=90) | 0 |
| High and/or Low Chloride | 0 |
| High and/or Low Total Calcium (n=90) | 0 |
| High and/or Low Inorganic Phosphorus (n=90) | 0 |
| Low Glucose (n=90) | 21 |
| High Glucose (n=90) | 1 |
| Low Fasting Glucose (n=28) | 3 |
| High Fasting Glucose (n=28) | 1 |
| High and/or Low Total Protein (n=90) | 0 |
| Low Albumin (n=90) | 0 |
| High Uric Acid (n=90) | 1 |
MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis: protein, glucose, blood, leukocyte esterase, RBC, WBC: \>= 2+ (or, if value \>= 4, or if pre-Rx value = 0 or 0.5, then \>= 2x or if pre-Rx value =1, then \>= 3, or if pre-Rx = 2 or 3, then \>= 4).
| participants | Abatacept Long Term Extension Study |
|---|---|
| High Urine Protein (n=89) | 6 |
| High Urine Glucose (n=89) | 2 |
| High Urine Blood (n=89) | 13 |
| High Urine Esterase (n=45) | 12 |
| High Urine WBC (n=51) | 26 |
| High Urine RBC (n=47) | 16 |
Collected over Short Term (ST) Study: Day 1 up to Day 113. LTE Study: Start of LTE Study up to 56 days post the last dose. Study initiated 2007 and completed LTE 2014.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Short Term Study: Subcutaneous (SC) Abatacept + Methotrexate | — | 2/51 (3.9%) | 16/51 (31.4%) |
| Short Term Study: SC Abatacept Monotherapy | — | 3/49 (6.1%) | 13/49 (26.5%) |
| Long Term Extension (LTE):125 mg SC Abatacept | — | 34/90 (37.8%) | 70/90 (77.8%) |
| Event | Short Term Study: Subcutaneous (SC) Abatacept + Methotrexate | Short Term Study: SC Abatacept Monotherapy | Long Term Extension (LTE):125 mg SC Abatacept |
|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/51 | 0/49 | 3/90 |
| Chest painGeneral disorders | 0/51 | 0/49 | 2/90 |
| CholelithiasisHepatobiliary disorders | 0/51 | 0/49 | 2/90 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/51 | 0/49 | 2/90 |
| Atrial fibrillationCardiac disorders | 0/51 | 0/49 | 2/90 |
| PneumoniaInfections and infestations | 0/51 | 1/49 | 1/90 |
| Lower Respiratory Tract InfectionInfections and infestations | 0/51 | 1/49 | 0/90 |
| Cartilage InjuryInjury, poisoning and procedural complications | 0/51 | 1/49 | 0/90 |
| Pneumocystis Jiroveci PneumoniaInfections and infestations | 1/51 | 0/49 | 0/90 |
| SyncopeNervous system disorders | 1/51 | 0/49 | 0/90 |
| Event | Short Term Study: Subcutaneous (SC) Abatacept + Methotrexate | Short Term Study: SC Abatacept Monotherapy | Long Term Extension (LTE):125 mg SC Abatacept |
|---|---|---|---|
| SinusitisInfections and infestations | 0/51 | 0/49 | 22/90 |
| Upper respiratory tract infectionInfections and infestations | 6/51 | 2/49 | 21/90 |
| Urinary tract infectionInfections and infestations | 1/51 | 3/49 | 17/90 |
| BronchitisInfections and infestations | 0/51 | 0/49 | 12/90 |
| NasopharyngitisInfections and infestations | 0/51 | 0/49 | 12/90 |
| HeadacheNervous system disorders | 5/51 | 3/49 | 5/90 |
| ContusionInjury, poisoning and procedural complications | 0/51 | 0/49 | 8/90 |
| HypertensionVascular disorders | 0/51 | 0/49 | 8/90 |
| FallInjury, poisoning and procedural complications | 0/51 | 0/49 | 8/90 |
| VomitingGastrointestinal disorders | 0/51 | 4/49 | 0/90 |
| Age, Continuous(years) | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort | Total |
|---|---|---|---|
| Median | 55.0 ± 11.5 | 54.0 ± 10.2 | 54.0 ± 10.9 |
| Sex: Female, Male(Participants) | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort | Total |
|---|---|---|---|
| Female | 34 | 41 | 75 |
| Male | 17 | 8 | 25 |
| Race/Ethnicity, Customized(participants) | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort | Total |
|---|---|---|---|
| White | 42 | 34 | 76 |
| Black | 7 | 4 | 11 |
| American Indian/Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 10 | 11 |
| Other races | 0 | 1 | 1 |
| Weight continuous(kilogram (Kg)) | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort | Total |
|---|---|---|---|
| Mean | 84.6 ± 18.8 | 81.6 ± 22.4 | 83.1 ± 20.6 |
| Weight customized(participants) | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort | Total |
|---|---|---|---|
| < 60 Kg | 4 | 8 | 12 |
| 60 - 100 Kg | 36 | 31 | 67 |
| > 100 Kg | 11 | 10 | 21 |
| Disease activity score C-reactive protein (DAS 28-CRP)(Units on a scale) | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort | Total |
|---|---|---|---|
| Mean | 5.1 ± 1.2 | 5.8 ± 1.5 | 5.4 ± 1.4 |
| Tender joints(tender joints) | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort | Total |
|---|---|---|---|
| Mean | 23.9 ± 18.0 | 24.3 ± 14.2 | 24.1 ± 16.2 |
| Swollen joints(swollen joints) | Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort | SC Abatacept Monotherapy Cohort | Total |
|---|---|---|---|
| Mean | 16.2 ± 12.0 | 18.3 ± 12.2 | 17.2 ± 12.1 |
5 further baseline measures are reported on the registry.
The record gives a start of Dec 2007, a primary completion of Dec 2008 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept